Latest news
Parkinson’s disease: dual-enzyme AAV gene therapy shows clean 12-month safety signal - Vera HealthVera Health · Fri, 07 Aug 2026 01:36:34 GMTFAST taps Apertura's BBB-crossing AAV platform to advance Angelman gene therapy - AllSciAllSci · Thu, 06 Aug 2026 08:01:27 GMTKriya Announces Publication of Preclinical Data Showing AAV-FGF21 Gene Therapy Extended Health Span and Lifespan in Aged Mice - BioSpaceBioSpace · Thu, 06 Aug 2026 02:31:45 GMTOpus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 19:39:16 GMTOnce again, child dies in gene-editing trial in China, rekindling debate on transparency and safety - STATSTAT · Wed, 05 Aug 2026 17:48:28 GMTGlymphatic gene therapy platform targets brain’s glial cells precisely - Drug Target ReviewDrug Target Review · Tue, 04 Aug 2026 12:49:50 GMTAAV vs. lentiviral vectors: gene therapy manufacturing platform selection - Drug Discovery NewsDrug Discovery News · Sat, 01 Aug 2026 18:52:05 GMTTSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1 - PR NewswirePR Newswire · Thu, 30 Jul 2026 07:00:00 GMT